PHGDH and melanoma: However, NCT-503 treatment did not reduce proliferation in the ZR-75-1 breast carcinoma cell line and the SK-MEL-2 malignant melanoma cell line, which both express low PHGDH levels4, suggesting that phenotypic consequences of the off-target effect described here vary among cell lines.